GLP-1 类似物 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-12. Anything still debated is marked as such rather than presented as settled.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Although commercial refrigeration quickly progressed, it had limitations that prevented it from moving into the household. First, most refrigerators were far too large. Some of the commercial units being used in 1910 weighed between five and two hundred tons. Second, commercial refrigerators were expensive to produce, purchase, and maintain. Lastly, these refrigerators were unsafe. It was not uncommon for commercial refrigerators to catch fire, explode, or leak toxic gases. Refrigeration did not become a household technology until these three challenges were overcome.
=== Selected papers === O. C. Sandall, C. J. King & C. R. Wilke, "The Relationship between Transport Properties and Rates of Freeze Drying of Poultry Meat", AIChE Jour., 13, 428-438 (1967). S. K. Chandrasekaran & C. J. King, "Multicomponent Diffusion and Vapor-Liquid Equilibria of Dilute Organic Components in Aqueous Sugar Solution", AIChE Jour., 18, 513-520 (1972). R. J. Bellows & C. J. King, "Freeze-drying of Aqueous Solutions: Maximum Allowable Operating Temperature", Cryobiology, 9, 559-561 (1972). T. G. Kieckbusch & C. J. King, "Volatiles Loss during Atomization in Spray Drying", AIChE Jour., 21, 718-725 (1980). G. E. Downton, J. L. Flores-Luna & C. J. King, "Mechanism of Stickiness in Hygroscopic, Amorphous Powders", Ind. Eng. Chem. Fundamentals, 21, 447-451 (1982). A. S. Kertes & C. J. King, "Extraction Chemistry of Fermentation Product Carboxylic Acids", Biotechnol. & Bioengg., 28, 269-282 (1986). C. J. King, "Separation Processes Based on Reversible Chemical Complexation", Ch. 15 in R. W. Rousseau, ed., Handbook of Separation Process Technology, pp. 760–774, Wiley, 1987. T. M. El-Sayed, D. A. Wallack & C. J. King, "Changes in Particle Morphology during Drying of Drops", Parts I & II, Ind. Engg. Chem. Research, 29, 2346-2354 (1990). C. J. King, "Amine-based System for Carboxylic Acid Recovery: Tertiary Amines and the proper choice of diluent allow extraction and recovery from water", CHEMTECH, 285-291 (May, 1992). L. A. Tung & C. J. King, "Sorption and Extraction of Lactic and Succinic Acids at pH>pKa1", Parts I & II, Ind. Engg. Chem. Res., 34, 3217-3229 (1994).
Baby monitor – a crib-side appliance for parents of infants that transmits the baby's sounds to a receiver carried by the parent, so they can monitor the baby while they are in other parts of the house. The wavebands used vary by region, but analog baby monitors generally transmit with low power in the 16, 9.3–49.9 or 900 MHz wavebands, and digital systems in the 2.4 GHz waveband. Many baby monitors have duplex channels so the parent can talk to the baby, and cameras to show video of the baby. Wireless microphone – a battery-powered microphone with a short-range transmitter that is handheld or worn on a person's body which transmits its sound by radio to a nearby receiver unit connected to a sound system. Wireless microphones are used by public speakers, performers, and television personalities so they can move freely without trailing a microphone cord. Traditionally, analog models transmit in FM on unused portions of the television broadcast frequencies in the VHF and UHF bands. Some models transmit on two frequency channels for diversity reception to prevent nulls from interrupting transmission as the performer moves around. While some consumer models use digital modulation in the 900 MHz, 2.4 GHz, or 6 GHz ISM bands, most professional wireless microphone and in-ear monitor (IEM) systems operate in the UHF TV band (typically 470–702 MHz). Modern developments include Wireless Multichannel Audio Systems (WMAS), which utilize wideband transmission to support high channel density within a single radio frequency carrier.
=== Marriage === Seligman writes: "Unlike money, which has at most a small effect, marriage is robustly related to happiness... In my opinion, the jury is still out on what causes the proven fact married people are happier than unmarried people." (pp. 55–56). Married persons report higher levels of happiness and well-being than single people. Other data has shown a spouse's happiness depends on the happiness of their partner. When asked, spouses reported similar happiness levels to each other. The data also shows the spouses' happiness level fluctuates similarly to one another. If the husband is having a bad week, the wife will similarly report she had a bad week. There is little data on alternatives like polyamory, although one study stated wife order in polygyny did not have a substantial effect on life or marital satisfaction over all. This study also found younger wives were happier than older wives. On the other hand, at least one large study in Germany found no difference in happiness between married and unmarried people. Studies have shown that married couples are consistently happier and more satisfied with their life than those who are single. Some research findings have indicated that marriage is the only real significant bottom-up predictor of life satisfaction for men and women, and that those people who have a higher life satisfaction prior to marriage, tend to have a happier marriage. Self-reported satisfaction typically drops as the years of marriage roll on, particularly for couples who have children compared to those who do not.
Sources: en.wikipedia.org
Aprataxin is 342 amino acids long and consists of FHA domain and HIT-ZnF catalyc core. It works by binding to adenylated DNA and removing AMP by catalytic side. Aprataxin is localised in the nucleus and mitochondria, which means aprataxin participates in mitochondrial DNA repair. This protein participates in base excision repair (BER) by returning abortive DNA ligation into scheduled repair by DNA polymerase beta, which would remove 5'-deoxyribosephosphate residue (dRP) and fill the gap; consequently, DNA ligase III-XRCC1 complex would seal the gap; consequently this mechanism is hampered in AOA1. Also, it might participate in microhomology-mediated end joining (MMEJ) by associating with XRCC1 and DNA ligase III and safeguarding DNA from abortive ligations by DNA ligase I, which might, again, be hampered in AOA1. iPSC with AOA1-associated mutation showed hindered differentiation into neurons which could be responsinble for early onset. Additionally, these neurons showed increased levels of cleaved PARP1 and decreased levels of APEX1. Due to the unique structure of chromatin in Purkinje cells, DNA damage (caused by aprataxin dysfunction) would hamper RNA polymerase II function, which would lead to improper splicing of some genes (such as: ITPR1, GRID2, CA8) and consequeent formation of R-loops; R-loops can exacerbate DNA damage. Because of dysregulation of genes, this would lead to ataxia. Decreased levels of albumin and elevated alpha-fetoprotein in AOA1 might be caused by transcriptional dysregulation in the liver.
Nor are rights of pre-emption to buy shares, nor rights of any party regarding claims by tort, contract or piercing the corporate veil to hold directors and shareholders accountable. However, Directives do require minimum rights on company formation, capital maintenance, accounting and audit, market regulation, board neutrality in a takeover bid, rules on mergers, and management of cross-border insolvency. The omission of minimum standards is important since the Court of Justice held in Centros that freedom of establishment requires companies operate in any member state they choose. This has been argued to risk a "race to the bottom" in standards, although the Court of Justice soon affirmed in Inspire Art that companies must still comply with proportionate requirements that are in the "public interest".
== External links == Histology image: 14805loa – Histology Learning System at Boston University Anatomy photo: Reproductive/mammal/ovary2/ovary5 - Comparative Organology at University of California, Davis - "Mammal, canine ovary (LM, High)" Anatomy photo: Reproductive/mammal/ovary5/ovary6 - Comparative Organology at University of California, Davis - "Mammal, bovine ovary (LM, Medium)" Anatomy Atlases – Microscopic Anatomy, plate 13.249 Slide at trinity.edu
Plasma is normally yellow due to bilirubin, carotenoids, hemoglobin, and transferrin. In abnormal cases, plasma can have varying shades of orange, green, or brown. The green color can be due to ceruloplasmin or sulfhemoglobin. The latter may form due to medicines that are able to form sulfonamides once ingested. A dark brown or reddish color can appear due to hemolysis, in which methemoglobin is released from broken blood cells. Plasma is normally relatively transparent, but sometimes it can be opaque. Opaqueness is typically due to elevated content of lipids like cholesterol and triglycerides.
Loughren (1923), electrical engineer, former president of the Institute of Radio Engineers Leslie White (1923), anthropologist known for his theories of the evolution of culture and for the scientific study of culture John Gassner (1924), historian of theater, Sterling Professor at Yale University Meyer Schapiro (1924), art historian Joseph Campbell (1925), mythologist Jerome Klein (1925), art historian and co-founder of the American Artists' Congress William York Tindall (1925), James Joyce scholar at Columbia University Lionel Trilling (1925), literary critic Dwight C. Miner (1926), historian Jacques Barzun (1927), cultural historian Elliott Van Kirk Dobbie, historian, scholar of Anglo-Saxon literature Robert C.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.